Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1992 May;47(5):349–354. doi: 10.1136/thx.47.5.349

Auranofin in the treatment of steroid dependent asthma: a double blind study.

G Nierop 1, W P Gijzel 1, E H Bel 1, A H Zwinderman 1, J H Dijkman 1
PMCID: PMC463749  PMID: 1609377

Abstract

BACKGROUND: Long term administration of oral corticosteroids in patients with asthma may be associated with serious side effects. Non-steroidal anti-inflammatory drugs, including gold salts, have been shown to reduce the need for systemic corticosteroid treatment in uncontrolled studies. The effect of oral gold (auranofin) on asthma symptoms, lung function, and the need for oral prednisone treatment was investigated. METHODS: A 26 week randomised, double blind, placebo controlled, parallel group trial of auranofin was performed in 32 patients with moderately severe chronic asthma who required an oral corticosteroid dose of at least 5 mg prednisone a day (or equivalent) or 2.5 mg/day prednisone plus more than 800 micrograms/day inhaled corticosteroids. Auranofin was given orally in a dose of 3 mg twice daily. Asthma symptoms, lung function, and adverse effects were assessed at regular intervals. After 12 weeks of treatment prednisone dosage was tapered down by 2.5 mg every two weeks if the patient was clinically stable. Asthma exacerbations were treated with short courses of high doses of oral steroids. RESULTS: Twenty eight of the 32 patients, 13 in the placebo group and 15 in the auranofin group, completed the study. The total corticosteroid reduction achieved after 26 weeks of treatment was significantly greater (4 mg) in the auranofin group than in the placebo group (0.3 mg). The number of exacerbations requiring an increase of steroids was greater in the placebo group (2.1) than in the active group (0.9). A significant increase in FEV1 of 6.4% predicted occurred in the auranofin group during the study and there was a reduction of asthma symptoms such as wheezing and cough. There was no difference between the groups in peak flow measurements or in the number of asthma attacks. The incidence of side effects of auranofin was low, but exacerbations of constitutional eczema were noticeable. CONCLUSION: Auranofin provides an effective adjunct to treatment for steroid dependent asthma, leading to a reduction of oral steroid dose.

Full text

PDF
349

Images in this article

352Image
on p.352

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. A new approach to the treatment of asthma. N Engl J Med. 1989 Nov 30;321(22):1517–1527. doi: 10.1056/NEJM198911303212206. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S70–S76. [PubMed] [Google Scholar]
  3. Barnes P. J. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol. 1989 Jun;83(6):1013–1026. doi: 10.1016/0091-6749(89)90441-7. [DOI] [PubMed] [Google Scholar]
  4. Bel E. H., Timmers M. C., Hermans J., Dijkman J. H., Sterk P. J. The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis. 1990 Jan;141(1):21–28. doi: 10.1164/ajrccm/141.1.21. [DOI] [PubMed] [Google Scholar]
  5. Bernstein D. I., Bernstein I. L., Bodenheimer S. S., Pietrusko R. G. An open study of auranofin in the treatment of steroid-dependent asthma. J Allergy Clin Immunol. 1988 Jan;81(1):6–16. doi: 10.1016/0091-6749(88)90213-8. [DOI] [PubMed] [Google Scholar]
  6. Blodgett R. C., Jr, Pietrusko R. G. Long-term efficacy and safety of auranofin: a review of clinical experience. Scand J Rheumatol Suppl. 1986;63:67–78. [PubMed] [Google Scholar]
  7. Cockcroft D. W., Murdock K. Y. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987 May;79(5):734–740. doi: 10.1016/0091-6749(87)90204-1. [DOI] [PubMed] [Google Scholar]
  8. Davis P., Miller C. L., Russell A. S. Effects of gold compounds on the function of phagocytic cells. I. Suppression of phagocytosis and the generation of chemiluminescence by polymorphonuclear leukocytes. J Rheumatol Suppl. 1982 Jul-Aug;8:18–24. [PubMed] [Google Scholar]
  9. Dimartino M. J., Walz D. T. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent. Inflammation. 1977 Jun;2(2):131–142. doi: 10.1007/BF00918675. [DOI] [PubMed] [Google Scholar]
  10. Eigen H., Reid J. J., Dahl R., Del Bufalo C., Fasano L., Gunella G., Sahlstrom K. K., Alanko K. L., Greenbaum J., Hagelund C. H. Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma. J Allergy Clin Immunol. 1987 Oct;80(4):612–621. doi: 10.1016/0091-6749(87)90016-9. [DOI] [PubMed] [Google Scholar]
  11. Honda Z., Iizasa T., Morita Y., Matsuta K., Nishida Y., Miyamoto T. Differential inhibitory effects of auranofin on leukotriene B4 and leukotriene C4 formation by human polymorphonuclear leukocytes. Biochem Pharmacol. 1987 May 1;36(9):1475–1481. doi: 10.1016/0006-2952(87)90113-4. [DOI] [PubMed] [Google Scholar]
  12. Klaustermeyer W. B., Noritake D. T., Kwong F. K. Chrysotherapy in the treatment of corticosteroid-dependent asthma. J Allergy Clin Immunol. 1987 May;79(5):720–725. doi: 10.1016/0091-6749(87)90202-8. [DOI] [PubMed] [Google Scholar]
  13. Kwong F. K., Sue M. A., Klaustermeyer W. B. Corticosteroid complications in respiratory disease. Ann Allergy. 1987 May;58(5):326–330. [PubMed] [Google Scholar]
  14. Lewis A. J., Cottney J., White D. D., Fox P. K., McNeillie A., Dunlop J., Smith W. E., Brown D. H. Action of gold salts in some inflammatory and immunological models. Agents Actions. 1980 Apr;10(1 Pt 2):63–77. doi: 10.1007/BF02024180. [DOI] [PubMed] [Google Scholar]
  15. Marone G., Columbo M., Galeone D., Guidi G., Kagey-Sobotka A., Lichtenstein L. M. Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents Actions. 1986 Apr;18(1-2):100–102. doi: 10.1007/BF01987994. [DOI] [PubMed] [Google Scholar]
  16. McFadden E. R., Jr Corticosteroids and cromolyn sodium as modulators of airway inflammation. Chest. 1988 Jul;94(1):181–184. doi: 10.1378/chest.94.1.181. [DOI] [PubMed] [Google Scholar]
  17. Morell F., Orriols R., Molina C. Usefulness of skin test in Farmer's lung. Chest. 1985 Feb;87(2):202–205. doi: 10.1378/chest.87.2.202. [DOI] [PubMed] [Google Scholar]
  18. Muranaka M., Miyamoto T., Shida T., Kabe J., Makino S., Okumura H., Takeda K., Suzuki S., Horiuchi Y. Gold salt in the treatment of bronchial asthma--a double-blind study. Ann Allergy. 1978 Feb;40(2):132–137. [PubMed] [Google Scholar]
  19. Muranaka M., Nakajima K., Suzuki S. Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salt. J Allergy Clin Immunol. 1981 May;67(5):350–356. doi: 10.1016/0091-6749(81)90079-8. [DOI] [PubMed] [Google Scholar]
  20. Parente J. E., Wong K., Davis P., Burka J. F., Percy J. S. Effects of gold compounds on leukotriene B4, leukotriene C4 and prostaglandin E2 production by polymorphonuclear leukocytes. J Rheumatol. 1986 Feb;13(1):47–51. [PubMed] [Google Scholar]
  21. Reed C. E. Aerosol glucocorticoid treatment of asthma. Adults. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S82–S88. [PubMed] [Google Scholar]
  22. Roisman F. R., Walz D. T., Finkelstein A. E. Superoxide radical production by human leukocytes exposed to immune complexes: inhibitory action of gold compounds. Inflammation. 1983 Dec;7(4):355–362. doi: 10.1007/BF00916300. [DOI] [PubMed] [Google Scholar]
  23. Scheinberg M. A., Santos L. M., Finkelstein A. E. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J Rheumatol. 1982 May-Jun;9(3):366–369. [PubMed] [Google Scholar]
  24. Small P. Anti-inflammatory therapy in asthma. Ann Allergy. 1989 Jun;62(6):481–482. [PubMed] [Google Scholar]
  25. Snyder R. M., Mirabelli C. K., Crooke S. T. The cellular pharmacology of auranofin. Semin Arthritis Rheum. 1987 Aug;17(1):71–80. doi: 10.1016/0049-0172(87)90017-5. [DOI] [PubMed] [Google Scholar]
  26. Takaishi T., Morita Y., Kudo K., Miyamoto T. Auranofin, an oral chrysotherapeutic agent, inhibits histamine release from human basophils. J Allergy Clin Immunol. 1984 Sep;74(3 Pt 1):296–301. doi: 10.1016/0091-6749(84)90261-6. [DOI] [PubMed] [Google Scholar]
  27. Thomson N. C. Nedocromil sodium: an overview. Respir Med. 1989 Jul;83(4):269–276. doi: 10.1016/s0954-6111(89)80195-7. [DOI] [PubMed] [Google Scholar]
  28. Truhan A. P., Ahmed A. R. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989 May;62(5):375–391. [PubMed] [Google Scholar]
  29. Walz D. T., DiMartino M. J., Griswold D. E., Intoccia A. P., Flanagan T. L. Biologic actions and pharmacokinetic studies of auranofin. Am J Med. 1983 Dec 30;75(6A):90–108. doi: 10.1016/0002-9343(83)90481-3. [DOI] [PubMed] [Google Scholar]
  30. Ward J. R., Williams H. J., Egger M. J., Reading J. C., Boyce E., Altz-Smith M., Samuelson C. O., Jr, Willkens R. F., Solsky M. A., Hayes S. P. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983 Nov;26(11):1303–1315. doi: 10.1002/art.1780261102. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES